BNZL:LSEBunzl plc Analysis

Bunzl plc is trading comfortably above its short‑term moving averages, with price sitting above the 20‑day SMA and the 50‑day SMA, indicating a bullish bias. The RSI sits in the upper‑mid‑50s, supporting continued upside momentum but not yet in overbought territory. However, the MACD histogram has turned slightly negative and the MACD line sits just below its signal, suggesting a modest near‑term bearish pressure. Volume has been trending lower, which could limit the strength of any short‑term rally toward the 2,800 resistance level. On the fundamentals side, the company posted a modest 0.3% revenue growth in the first half and has upgraded its 2026 guidance, backed by a strong acquisition in the Australian healthcare segment. The dividend yield of 2.7% with a payout ratio just above 50% appears sustainable given solid operating cash flow and a healthy free cash flow generation.
Despite the positive operational backdrop, the discounted cash‑flow model values the stock around £1,800, well below the current market price of £2,708, flagging a significant overvaluation. The sector is defensive with low cyclicality, and the beta is near zero, implying limited market‑wide volatility exposure. Nonetheless, the 30‑day price volatility of roughly 23% and a recent drawdown of over 23% highlight a degree of price risk. Overall, the stock offers a reliable dividend and stable cash generation, but the pricing premium and mixed technical signals suggest a cautious stance.